Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that the results from its Proof-of-Concept trial evaluating lanifibranor in combination with empagliflozin for the treatment of MASH have been selected to be presented by Dr. Onno Holleboom in an oral plenary presentation at the upcoming Steatotic Liver Disease (SLD) Summit 2025 hosted by the European Association for the Study of the Liver (EASL) on January 23-25 in Estoril, Portugal.